Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure by enhancing uveoscleral outflow, providing long‑term control of disease progression and preserving visual function.

GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable logistics across multiple continents.

Latanoprost is used in the management of ocular conditions that require reduction of intra‑ocular pressure. - Primary open-angle glaucoma: reduces intra‑ocular pressure to prevent optic nerve damage. - Secondary open-angle glaucoma: lowers intra‑ocular pressure to slow disease progression. - Ocular hypertension: decreases intra‑ocular pressure to reduce the risk of developing glaucoma. - Pseudoexfoliative glaucoma: lowers intra‑ocular pressure to manage this secondary form of open-angle glaucoma. - Ocular hypertension in patients with a family history of glaucoma: reduces pressure to lower conversion risk.

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: transient hyperemia of the conjunctiva that usually resolves without treatment. - Increased eyelash growth: longer, thicker lashes may appear, often considered a cosmetic effect. - Iris pigmentation: gradual darkening of eye color, typically irreversible and more noticeable in lighter eyes. - Eye irritation: burning or stinging sensation after instillation, generally mild and short‑lasting.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract that may cause pain, photophobia and requires prompt medical management. - Macular edema: swelling of the central retina that can affect visual acuity and may need specialist intervention.

Before prescribing Latanoprost, clinicians should consider several precautionary measures to ensure safe use. - Baseline intra‑ocular pressure assessment: measure IOP prior to initiating therapy. - Monitor iris color changes: observe for gradual darkening during treatment. - Avoid use in active ocular inflammation: contraindicated in uveitis or conjunctivitis. - Caution in patients with herpetic eye disease: may trigger reactivation. - Inform patients about possible eyelash and peri‑ocular skin changes. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, influencing its efficacy or safety.

Major Interactions (Avoid): - Nonsteroidal anti‑inflammatory eye drops: may diminish Latanoprost’s IOP‑lowering effect. - Systemic prostaglandin synthesis inhibitors (e.g., indomethacin): can antagonize the drug’s mechanism.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP reduction may increase risk of hypotony. - Carbonic anhydrase inhibitor eye drops: combined use can lead to excessive pressure lowering. - Cholinergic agents (e.g., pilocarpine): may increase risk of ocular inflammation.